probucol has been researched along with Cardiomyopathies in 9 studies
Probucol: A drug used to lower LDL and HDL cholesterol yet has little effect on serum-triglyceride or VLDL cholesterol. (From Martindale, The Extra Pharmacopoeia, 30th ed, p993).
probucol : A dithioketal that is propane-2,2-dithiol in which the hydrogens attached to both sulfur atoms are replaced by 3,5-di-tert-butyl-4-hydroxyphenyl groups. An anticholesteremic drug with antioxidant and anti-inflammatory properties, it is used to treat high levels of cholesterol in blood.
Cardiomyopathies: A group of diseases in which the dominant feature is the involvement of the CARDIAC MUSCLE itself. Cardiomyopathies are classified according to their predominant pathophysiological features (DILATED CARDIOMYOPATHY; HYPERTROPHIC CARDIOMYOPATHY; RESTRICTIVE CARDIOMYOPATHY) or their etiological/pathological factors (CARDIOMYOPATHY, ALCOHOLIC; ENDOCARDIAL FIBROELASTOSIS).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Rats were either administered freshly prepared garlic homogenate (250 and 500 mg/kg daily, orally, for 30 days) or probucol (cumulative dose, 120 mg/kg body weight divided in 12, i." | 3.72 | Protection against acute adriamycin-induced cardiotoxicity by garlic: role of endogenous antioxidants and inhibition of TNF-alpha expression. ( Banerjee, SK; Dinda, AK; Maulik, M; Maulik, SK; Mukherjee, S; Talwar, KK, 2003) |
| "Melatonin and probucol were equally effective in inhibiting the increase in myocardial TBARS as well as zinc levels, suggesting that myocardial zinc accumulation might be a protective response against adriamycin-induced oxidative stress." | 1.30 | Zinc accumulation in adriamycin-induced cardiomyopathy in rats: effects of melatonin, a cardioprotective antioxidant. ( Hayakawa, M; Hayakawa, T; Ito, T; Kaneko, S; Kawakami, K; Matsui, H; Mokuno, S; Morishima, I; Numaguchi, Y; Okumura, K; Toki, Y, 1999) |
| "Probucol treatment modulated adriamycin-induced cardiomyopathic changes and increased glutathione peroxidase and superoxide dismutase activities." | 1.30 | Mechanisms of beneficial effects of probucol in adriamycin cardiomyopathy. ( Danelisen, I; Hasinoff, BB; Iliskovic, N; Li, T; Malisza, KL; Singal, PK, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (66.67) | 18.2507 |
| 2000's | 2 (22.22) | 29.6817 |
| 2010's | 1 (11.11) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Walker, JR | 1 |
| Sharma, A | 1 |
| Lytwyn, M | 1 |
| Bohonis, S | 1 |
| Thliveris, J | 1 |
| Singal, PK | 6 |
| Jassal, DS | 1 |
| Mukherjee, S | 1 |
| Banerjee, SK | 1 |
| Maulik, M | 1 |
| Dinda, AK | 1 |
| Talwar, KK | 1 |
| Maulik, SK | 1 |
| Siveski-Iliskovic, N | 2 |
| Hill, M | 2 |
| Thomas, TP | 1 |
| Li, T | 4 |
| Chow, DA | 1 |
| Matsui, H | 2 |
| Okumura, K | 2 |
| Mukawa, H | 1 |
| Hibino, M | 1 |
| Toki, Y | 2 |
| Ito, T | 2 |
| Iliskovic, N | 2 |
| Kumar, D | 2 |
| Morishima, I | 1 |
| Kaneko, S | 1 |
| Numaguchi, Y | 1 |
| Kawakami, K | 1 |
| Mokuno, S | 1 |
| Hayakawa, M | 1 |
| Hayakawa, T | 1 |
| Hasinoff, BB | 1 |
| Malisza, KL | 1 |
| Danelisen, I | 2 |
| Kirshenbaum, LA | 1 |
2 reviews available for probucol and Cardiomyopathies
| Article | Year |
|---|---|
Combination therapy with probucol prevents adriamycin-induced cardiomyopathy.
Topics: Animals; Antioxidants; Cardiomyopathies; Doxorubicin; Drug Therapy, Combination; Free Radical Scaven | 1995 |
Adriamycin cardiomyopathy: pathophysiology and prevention.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; | 1997 |
7 other studies available for probucol and Cardiomyopathies
| Article | Year |
|---|---|
The cardioprotective role of probucol against anthracycline and trastuzumab-mediated cardiotoxicity.
Topics: Analysis of Variance; Animals; Anthracyclines; Antibiotics, Antineoplastic; Antibodies, Monoclonal; | 2011 |
Protection against acute adriamycin-induced cardiotoxicity by garlic: role of endogenous antioxidants and inhibition of TNF-alpha expression.
Topics: Animals; Antioxidants; Body Weight; Cardiomyopathies; Catalase; Doxorubicin; Garlic; Gene Expression | 2003 |
Probucol protects against adriamycin cardiomyopathy without interfering with its antitumor effect.
Topics: Animals; Antioxidants; Cardiomyopathies; Doxorubicin; Drug Interactions; Hemodynamics; Lipid Peroxid | 1995 |
Increased oxysterol contents in diabetic rat hearts: their involvement in diabetic cardiomyopathy.
Topics: Animals; Anticholesteremic Agents; Cardiomyopathies; Diabetes Mellitus, Experimental; Hydroxycholest | 1997 |
Zinc accumulation in adriamycin-induced cardiomyopathy in rats: effects of melatonin, a cardioprotective antioxidant.
Topics: Animals; Antioxidants; Ascites; Body Weight; Cardiomyopathies; Doxorubicin; Heart Ventricles; Lipid | 1999 |
Mechanisms of beneficial effects of probucol in adriamycin cardiomyopathy.
Topics: Animals; Antibiotics, Antineoplastic; Anticholesteremic Agents; Cardiomyopathies; Cholesterol; Crice | 1999 |
Apoptosis in adriamycin cardiomyopathy and its modulation by probucol.
Topics: Animals; Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Cardiomyopathies; Caspase 3; | 2001 |